University of Oxford and OSI are set to exit the medical diagnostics software provider in a flotation with a $75m placeholder target.
Perspectum, a UK-based diagnostics technology developer spun out of University of Oxford, filed on Friday to raise up to $75m in an initial public offering on the Nasdaq Global Select Market.
Founded in 2012, Perspectum has built a medical imaging software tool designed to help healthcare providers diagnose metabolic disorders and cancers.
The company intends to use the IPO proceeds and $23.3m of cash on hand to develop new products focused on diabetes and kidney disease while expanding its presence in the US market.
University of Oxford and its venture fund, Oxford Sciences Innovation (OSI), backed a $36m series B round in April 2020 that was co-led by Blue Venture Fund, a vehicle that invests on behalf of the 35 members of insurance group Blue Cross Blue Shield Association, and growth capital firm HealthQuest Capital. The series B round also included Puhua Capital and Li-Fa Global Investments.
OSI (6.3%) and University of Oxford (6%) are both among its notable shareholders, while family office Westgrove Partners owns the largest stake in the company (8.3%). Blue Venture Fund and HealthQuest Partners III own 7.9% each.
Citigroup, Barclays, Stifel and Canaccord Genuity have been appointed joint book-running managers for the offering.
– A version of this article first appeared on our sister site, Global Corporate Venturing.